Name：SHENG Weijin

Department：Oncology

Tel: (8610)63180504

Email: swj_zjnb@ imb.cams.cn

Education & Research Experience

2017/07– Now Associate Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2009/09– 2017/06 Research Assistant, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2006/09– 2009/06 Ph.D. in Microbial and Biochemical Pharmacy, Peking Union Medical College

2002/09– 2005/06 M.S. in Microbial and Biochemical Pharmacy, Jilin University

1998/09– 2002/06 B.E. in Bioengineering, Jiangnan University

Research Field：

1) Anti-tumor recombinant protein；2) Antibody drug conjugate; 3) Immunotherapy drugs for tumor

Research Interests：

Dr. Sheng is currently engaged in new anti-tumor drugs and pharmacological activity. She has successfully prepared a number of recombinant proteins with anti-tumor activity. She presided over the research projects including the National Natural Science Foundation and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences, and participated the projects such as National High Technology Research and Development Program of China, the National Basic Research Program of China and the Major Science and Technology Projects of China.

Selected Publications

1. Sheng W, Geng J, Li L, Shang Y, Jiang M, Zhen Y^*. An albuminbinding domain and targeting peptidebased recombinant protein and its enediyneintegrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with Kras mutation. Oncol Rep (Engl). 2020, 43(3): 851-863.

2. Geng J, Wang Y, Zhang L, Wang R, Li C, Sheng W^*, et al. The cajanine derivative LJ101019C regulates the proliferation and enhances the activity of NK cells via Kv1.3 channel-driven activation of the AKT/mTOR pathway. Phytomedicine (Engl). 2020, 66(1): 153113.

3. Sheng W, Gong J, Jiang M, Zhen Y^*, et al. A recombinant scFv and NGR motif-integrated fusion protein that bi-targets EGFR/CD13 inducing apoptosis and blocking tube formation, Oncol Rep (Engl). 2017, 38(12): 3507-3514.

4. Sheng W, Shang Y Li L, Zhen Y^*, et al. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity. Anti-cancer Drugs (Engl). 2014, 25(1): 82-91.

5. Sheng W, Shang Y, Miao Q, Zhen Y^*, et al. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue that are directed against epidermal growth factor receptor. Anti-cancer Drugs (Engl). 2012, 23(4): 406-415.